For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Research and development | 3,073,000 | 2,002,000 | 1,681,000 | 4,292,000 |
| General and administrative | 2,157,000 | 1,957,000 | 3,811,000 | 2,579,000 |
| Impairment loss on intangible assets | - | 28,700,000 | - | - |
| Total operating expenses | 5,230,000 | 32,659,000 | 5,492,000 | 6,871,000 |
| Loss from operations | -5,230,000 | -32,659,000 | -5,492,000 | -6,871,000 |
| Other (expense) income, net | -608,000 | -20,000 | -89,000 | 49,000 |
| Income tax benefit | - | -712,000 | - | - |
| Net loss | -5,838,000 | -31,967,000 | -5,581,000 | -6,822,000 |
| Unrealized gain on investments, net of tax of 0 | 0 | 18,000 | 0 | 12,000 |
| Foreign currency translation adjustments | 0 | -36,000 | 0 | -24,000 |
| Total other comprehensive loss | 0 | -18,000 | 0 | -12,000 |
| Total comprehensive loss | -5,838,000 | -31,985,000 | -5,581,000 | -6,834,000 |
| Basic EPS | -0.19 | -1.091 | -0.21 | -0.28 |
| Diluted EPS | -0.19 | -1.091 | -0.21 | -0.28 |
| Basic Average Shares | 30,354,647 | 29,314,367 | 26,361,386 | 24,187,536 |
| Diluted Average Shares | 30,354,647 | 29,314,367 | 26,361,386 | 24,187,536 |
Rein Therapeutics, Inc. (RNTX)
Rein Therapeutics, Inc. (RNTX)